Cipla Q3 Results: Pharmaceutical major Cipla on Tuesday reported a 49 per cent year-on-year (YoY) increase in its consolidated net profit for the December quarter (Q3 FY25) at Rs 1,574.6 crore, from ...
HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...
Cipla's stock settled 2.2% higher at ₹1,427 on Tuesday on the National Stock Exchange. The company expects to launch its breast cancer drug Abraxane, which was originally slated for a rollout in ...
That more than made up for a 1% drop in sales in North America, Cipla's second-biggest market, and helped the company's total revenue climb 7.1% to 70.73 billion rupees, surpassing market ...
That more than made up for a 1% drop in sales in North America, Cipla's second-biggest market, and helped the company's total revenue climb 7.1% to 70.73 billion rupees, surpassing market ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果